Spruce Biosciences, Inc. (SPRB)
NASDAQ: SPRB · Real-Time Price · USD
63.40
+4.75 (8.10%)
At close: Aug 25, 2026, 4:00 PM EDT
64.51
+1.11 (1.75%)
After-hours: Aug 25, 2026, 7:52 PM EDT
Spruce Biosciences Employees
Spruce Biosciences had 22 employees as of June 30, 2026. The number of employees increased by 13 or 144.44% compared to the same quarter last year.
Employees
22
Change
13
Growth
144.44%
Revenue / Employee
n/a
Profits / Employee
-$2,334,227
Market Cap
182.21M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2026 | 22 | 13 | 144.44% |
| Mar 31, 2026 | 14 | -6 | -30.00% |
| Dec 31, 2025 | 8 | -13 | -61.90% |
| Sep 30, 2025 | 9 | -13 | -59.09% |
| Jun 30, 2025 | 9 | -13 | -59.09% |
| Mar 31, 2025 | 20 | -2 | -9.09% |
| Dec 31, 2024 | 21 | -8 | -27.59% |
| Sep 30, 2024 | 22 | -9 | -29.03% |
| Jun 30, 2024 | 22 | -10 | -31.25% |
| Mar 31, 2024 | 22 | -8 | -26.67% |
| Dec 31, 2023 | 29 | 2 | 7.41% |
| Sep 30, 2023 | 31 | 9 | 40.91% |
| Jun 30, 2023 | 32 | 15 | 88.24% |
| Mar 31, 2023 | 30 | 14 | 87.50% |
| Dec 31, 2022 | 27 | 12 | 80.00% |
| Sep 30, 2022 | 22 | 3 | 15.79% |
| Jun 30, 2022 | 17 | -4 | -19.05% |
| Mar 31, 2022 | 16 | -3 | -15.79% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| LENZ Therapeutics | 152 |
| Tenaya Therapeutics | 70 |
| Connect Biopharma Holdings | 64 |
| Milestone Pharmaceuticals | 38 |
| Aardvark Therapeutics | 28 |
| Unicycive Therapeutics | 22 |
| Outlook Therapeutics | 17 |
| Equillium | 15 |
SPRB News
- 1 day ago - Spruce Biosciences Announces Positive Pre-BLA Meetings with FDA and Confirms BLA Submission for TA-ERT on Track for Q4 2026 - Business Wire
- 8 days ago - Spruce Biosciences price target lowered to $104 from $123 at Guggenheim - TheFly
- 8 days ago - Cure Sanfilippo, National MPS agree to make $5.5M investment in Spruce - TheFly
- 8 days ago - Spruce Biosciences reports Q2 EPS ($6.68), consensus ($5.93) - TheFly
- 8 days ago - Spruce Biosciences sees cash runway into 2H27 - TheFly
- 8 days ago - Spruce Biosciences price target lowered to $144 from $150 at Citizens - TheFly
- 13 days ago - Spruce Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates - Business Wire
- 13 days ago - Cure Sanfilippo Foundation and National MPS Society Make $5.5 Million Strategic Investment in Spruce Biosciences - Business Wire